全文获取类型
收费全文 | 14880篇 |
免费 | 619篇 |
国内免费 | 361篇 |
专业分类
耳鼻咽喉 | 14篇 |
儿科学 | 363篇 |
妇产科学 | 432篇 |
基础医学 | 1237篇 |
口腔科学 | 67篇 |
临床医学 | 1157篇 |
内科学 | 5488篇 |
皮肤病学 | 77篇 |
神经病学 | 388篇 |
特种医学 | 139篇 |
外科学 | 849篇 |
综合类 | 2331篇 |
预防医学 | 1087篇 |
眼科学 | 61篇 |
药学 | 1628篇 |
4篇 | |
中国医学 | 419篇 |
肿瘤学 | 119篇 |
出版年
2023年 | 119篇 |
2022年 | 230篇 |
2021年 | 405篇 |
2020年 | 348篇 |
2019年 | 439篇 |
2018年 | 414篇 |
2017年 | 334篇 |
2016年 | 323篇 |
2015年 | 343篇 |
2014年 | 968篇 |
2013年 | 882篇 |
2012年 | 860篇 |
2011年 | 1060篇 |
2010年 | 772篇 |
2009年 | 931篇 |
2008年 | 964篇 |
2007年 | 916篇 |
2006年 | 754篇 |
2005年 | 639篇 |
2004年 | 506篇 |
2003年 | 372篇 |
2002年 | 251篇 |
2001年 | 252篇 |
2000年 | 217篇 |
1999年 | 181篇 |
1998年 | 140篇 |
1997年 | 112篇 |
1996年 | 118篇 |
1995年 | 129篇 |
1994年 | 115篇 |
1993年 | 97篇 |
1992年 | 84篇 |
1991年 | 91篇 |
1990年 | 73篇 |
1989年 | 83篇 |
1988年 | 99篇 |
1987年 | 64篇 |
1986年 | 59篇 |
1985年 | 140篇 |
1984年 | 143篇 |
1983年 | 72篇 |
1982年 | 101篇 |
1981年 | 103篇 |
1980年 | 86篇 |
1979年 | 90篇 |
1978年 | 62篇 |
1977年 | 57篇 |
1976年 | 46篇 |
1975年 | 38篇 |
1973年 | 33篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
21.
《Joint, bone, spine : revue du rhumatisme》2019,86(3):335-341
ObjectiveRetinol-binding protein 4 (RBP4), systemic inflammation and insulin resistance (IR) are linked, yet the determinants of RBP4 and its impact on IR in rheumatoid arthritis (RA) are incompletely understood. The aim of this study was to explore the prevalence of IR in RA and investigate whether the serum levels of RBP4 were associated with IR in patients with RA.MethodsIn this study, 403 individuals with newly diagnosed and untreated RA were consecutively recruited. We calculated the Disease Activity Score assessed using 28-joint counts for swelling and tenderness (DAS28). Levels of serum RBP4, interleukin-6 (IL-6) and tumor necrosis factor (TNF) α were tested. IR was defined as Homeostasis model assessment for insulin resistance (HOMA-IR) index greater than or equal 2.40.ResultsIn those 403 patients, 68 (16.9%) were male and the median age was 43 years (IQR: 36–52). There was an evidently positive correlation between increased serum levels of RBP4 and increasing severity of RA (DAS28) (r = 0.403, P < 0.001). Furthermore, a modest positive correlation between levels of serum RBP4 and HOMA-IR score (r = 0.251; P < 0.0001) was found. Eighty-five patients (21.1%) in patients with RA were defined as IR (HOMA-IR ≥ 2.40), which was significantly higher than in normal cases (4.7%). In the patients with IR, serum levels of RBP4 were higher when compared with those in patients free-IR P < 0.001. The IR distribution across the quartiles of RBP4 ranged between 5.0% (first quartile) to 39.0% (fourth quartile), P for trend < 0.001. For each 1unit increase of RBP4, the unadjusted and adjusted risk of IR increased by 8% (OR: 1.08; 95% CI: 1.05–1.11, P < 0.001) and 5% (1.05; 1.02–1.09, P = 0.001), respectively. When RBP4 was added to the model containing established significant risk factors, AUROC (standard error) was increased from 0.768 (0.025) to 0.807(0.021). A significant difference in the AUC between the established risk factors alone and the addition of RBP4 was observed (difference, 0.039[0.004]; P = 0.02).ConclusionElevated serum levels of RBP4 were associated with increased risk of IR and might be useful in identifying RA at risk for IR and/or impaired glucose tolerance for early prevention strategies, especially in obese and women patients 相似文献
22.
目的探讨药师参与2型糖尿病患者在使用胰岛素治疗过程中对患者治疗效果的影响。方法选择该院在2019年5月—2020年5月门诊收治的200例2型糖尿病患者为研究对象,随机分为实验组和观察组,每组100例,实验组患者在治疗期间药师参与患者治疗全过程;观察组按照常规治疗方案进行治疗;观察患者各项指标变化情况。结果实验组在经过药师指导后,糖化血红蛋白、空腹血糖、患者用药依从性明显优于观察组,差异有统计学意义(P<0.05)。结论药师参与2型糖尿病患者使用胰岛素治疗期间,能够明显提高患者的治疗效果和生活质量,实现了医药护理共同协作,值得被医护人员在临床中广泛应用,并进行大力推广及宣传。 相似文献
23.
目的研究肥胖型2型糖尿病患者联合采用西格列汀、二甲双胍治疗的临床效果。方法选择2018年10月—2020年4月该院100例肥胖型2型糖尿病患者为研究对象,采用随机数表法分成常规组和治疗组,每组50例。常规组予二甲双胍治疗,治疗组予二甲双胍+西格列汀治疗。比较两组治疗效果、血糖指标、体脂含量、胰岛功能指标及不良反应。。结果两组治疗效果比较,差异有统计学意义(P<0.05)。治疗后常规组血糖指标高于治疗组,差异有统计学意义(t=8.183、4.828、18.158,P<0.05)。治疗后常规组体脂含量高于治疗组,差异有统计学意义(t=5.993、7.657、4.420,P<0.05)。治疗后两组胰岛功能比较,差异有统计学意义(t=5.898、5.283、16.033,P<0.05)。常规组不良反应总发生率低于治疗组,但差异无统计学意义(χ2=0.136,P=0.712)。结论西格列汀、二甲双胍联合治疗肥胖型2型糖尿病效果确切。 相似文献
24.
Ana M. Gómez Angelica Imitola Diana Henao Maira García-Jaramillo Marga Giménez Clara Viñals Bruno Grassi Mariana Torres Isabella Zuluaga Oscar Mauricio Muñoz Martin Rondón Fabián León-Vargas Ignacio Conget 《Diabetes & Metabolic Syndrome: Clinical Research & Reviews》2021,15(1):267-272
Background and aimsDespite using sensor-augmented pump therapy (SAPT) with predictive low-glucose management (PLGM), hypoglycemia is still an issue in patients with type 1 Diabetes (T1D). Our aim was to determine factors associated with clinically significant hypoglycemia (<54 mg/dl) in persons with T1D treated with PLGM-SAPT.Methodology: This is a multicentric prospective real-life study performed in Colombia, Chile and Spain. Patients with T1D treated with PLGM-SAPT, using sensor ≥70% of time, were included. Data regarding pump and sensor use patterns and carbohydrate intake from 28 consecutive days were collected. A bivariate and multivariate Poisson regression analysis was carried out, to evaluate the association between the number of events of <54 mg/dl with the clinical variables and patterns of sensor and pump use.Results188 subjects were included (41 ± 13.8 years-old, 23 ± 12 years disease duration, A1c 7.2% ± 0.9). The median of events <54 mg/dl was four events/patient/month (IQR 1–10), 77% of these events occurred during day time. Multivariate analysis showed that the number of events of hypoglycemia were higher in patients with previous severe hypoglycemia (IRR1.38; 95% CI 1.19–1.61; p < 0.001), high glycemic variability defined as Coefficient of Variation (CV%) > 36% (IRR 2.09; 95%CI 1.79–2.45; p < 0.001) and hypoglycemia unawareness. A protector effect was identified for adequate sensor calibration (IRR 0.77; 95%CI 0.66–0.90; p:0.001), and the use of bolus wizard >60% (IRR 0.74; 95%CI 0.58–0.95; p:0.017).ConclusionIn spite of using advanced SAPT, clinically significant hypoglycemia is still a non-negligible risk. Only the identification and intervention of modifiable factors could help to prevent and reduce hypoglycemia in clinical practice. 相似文献
25.
26.
《Diabetes & Metabolic Syndrome: Clinical Research & Reviews》2019,13(1):104-109
AimsThis study aims to evaluate the glycemic profile and outcomes of Indonesian diabetic pregnant mothers based on their methods of therapy and review current international as well as national guidelines on management of diabetes in pregnancy.Materials and methodsData was obtained from medical records of Hermina-Podomoro Hospital. Subjects were grouped based on therapy – nutrition therapy only, insulin and oral anti-diabetics group.ResultsForty-five subjects were obtained with an average age of 31-years. Around thirty-five percent of patients were given nutrition therapy only, 55.6% were using insulin and 8.8% were using oral anti-diabetics. Oral anti-diabetics users showed worse glycemic profile among the three groups. Six-patients suffered from IUFD with the highest proportion found in oral anti-diabetics users.ConclusionThe above results show the negative impacts of DM on pregnant mothers and the unborn. Caution is advised on the use of oral anti-diabetics as it may increase the risk of infant mortality. Increased monitoring and prenatal services for DM patients are essential in achieving blood glucose targets. 相似文献
27.
S. Kim M.J. Graham R.G. Lee L. Yang S. Kim V. Subramanian J.D. Layne L. Cai R.E. Temel D. Shih A.J. Lusis J.A. Berliner S. Lee 《Nutrition, metabolism, and cardiovascular diseases : NMCD》2019,29(3):306-315
Background and aims
Heparin-binding EGF-like growth factor (HB-EGF) is a representative EGF family member that interacts with EGFR under diverse stress environment. Previously, we reported that the HB-EGF-targeting using antisense oligonucleotide (ASO) effectively suppressed an aortic aneurysm in the vessel wall and circulatory lipid levels. In this study, we further examined the effects of the HB-EGF ASO administration on the development of hyperlipidemia-associated atherosclerosis using an atherogenic mouse model.Methods and results
The male and female LDLR deficient mice under Western diet containing 21% fat and 0.2% cholesterol content were cotreated with control and HB-EGF ASOs for 12 weeks. We observed that the HB-EGF ASO administration effectively downregulated circulatory VLDL- and LDL-associated lipid levels in circulation; concordantly, the HB-EGF targeting effectively suppressed the development of atherosclerosis in the aorta. An EGFR blocker BIBX1382 administration suppressed the hepatic TG secretion rate, suggesting a positive role of the HB-EGF signaling for the hepatic VLDL production. We newly observed that there was a significant improvement of the insulin sensitivity by the HB-EGF ASO administration in a mouse model under the Western diet as demonstrated by the improvement of the glucose and insulin tolerances.Conclusion
The HB-EGF ASO administration effectively downregulated circulatory lipid levels by suppressing hepatic VLDL production rate, which leads to effective protection against atherosclerosis in the vascular wall. 相似文献28.
《Diabetes & Metabolic Syndrome: Clinical Research & Reviews》2019,13(3):2208-2213
AimsGlucose tolerance abnormalities are frequently observed in patients with chronic liver disease (CLD). Insulin resistance (IR) has been suggested to be a major factor responsible for these abnormalities in CLD. However studies relating IR with severity of CLD are scarce in Nigeria. This study assessed insulin resistance and glucose tolerance abnormalities in CLD and their relationship with the severity of CLD in a tertiary hospital in South-West, Nigeria.MethodsThis cross sectional study involved 100 subjects with CLD. Ethical clearance was obtained and informed consent was granted by participants. Participants were interviewed using a structured proforma; physical examination and relevant investigations were performed. Insulin resistance was measured using the homeostasis model assessment (HOMA-IR) Data was analysed using Statistical Package for Social Sciences version 20.0 and p value of <0.05 was considered significant.ResultsMean age of the study participants was 51.9 ± 11.9 years, and mean duration of CLD was 15.9 ± 5.8 months. Glucose tolerance abnormalities were present in 66 subjects (66%) and increased from 16.1% in Child Pugh's class A to 90.0% in class C.HOMA-IR positively correlated with age, body mass index, serum blood glucose, duration and severity of CLD. Increasing age, presence of hepatocellular carcinoma, Child Pugh's class B and class C were associated with glucose tolerance abnormalities.ConclusionGlucose tolerance abnormalities and insulin resistance were highly prevalent among chronic liver disease subjects studied and seemed to parallel the severity of CLD, determined by the Child Pugh's score. 相似文献
29.
目的观察妇科腹腔镜手术围术期碳水化合物口服疗法和传统禁饮食方案两种不同的临床处理措施对于术后胰岛素抵抗(IR)的影响。
方法选取2018年2月至8月入住徐州医科大学附属医院妇科,行腹腔镜下全子宫切除手术的非糖尿病患者共98例,将采用围术期碳水化合物口服疗法者作为观察组(50例),采用传统禁饮食方案者作为对照组(48例)。检测所有病例的术前、术后第1天及第3天的空腹血糖(FPG)及空腹胰岛素(FINS),并利用稳态模式评估法计算稳态模型胰岛素抵抗指数(HOME-IR)。对于观察组与对照组患者术前、术后第1天和术后第3天的FPG、FINS和HOME-IR等指标,组间比较采用独立样本t检验。两组患者术后腹胀、术后24 h通气、术后发热的发生情况的比较采用确切概率法检验。
结果观察组与对照组比较,术前和术后第1天FPG差异无统计学意义(P均>0.05),术后第3天FPG明显降低[(4.34±0.59)mmol/L vs (4.96±0.64)mmol/L],差异有统计学意义(t=-4.96,P=0.002)。观察组与对照组比较,术前和术后第1天FINS差异无统计学意义(P均>0.05),术后第3天FINS明显降低[(45.39±13.55)mIU/L vs (51.18±9.34) mIU/L],差异有统计学意义(t=-2.46,P=0.033)。观察组与对照组比较,术前HOME-IR差异无统计学意义(P>0.05),术后第1天和术后第3天HOME-IR明显降低[(13.08±4.80)vs (15.03±4.11);(9.37±3.65)vs (11.30±2.55)],差异有统计学意义(t=-0.69,P=0.042;t=-3.99,P=0.033)。两组患者术后其他观察指标比较,观察组术后24 h通气率与对照组比较明显增高(76.0% vs 64.6%),差异有统计学意义(P=0.045)。两组患者在术后腹胀、术后发热的发生率方面差异无统计学意义(P均>0.05)。两组患者均未发生术中误吸。
结论妇科腹腔镜手术围术期应用碳水化合物口服疗法较传统禁饮食方案,能有效减轻术后IR程度,促进术后康复进程,且不增加围术期并发症的发生率。 相似文献
30.
X. Cui B. Wang Y. Wu L. Xie P. Xun Q. Tang W. Cai X. Shen 《Nutrition, metabolism, and cardiovascular diseases : NMCD》2019,29(5):467-473